EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis

Hosam Abdel-Fattah Abo-Elnasr, Mohamed Abdelrahman Alhefnawy, Mahmoud Farag, Mohamed Aboulfotouh El Gharably

Urology Research and Practice · 14.05.2026 · 52 · 1-9

DOI: 10.5152/tud.2026.26009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urology Research and Practice, online erschienen am 14.05.2026. Verfasst von Hosam Abdel-Fattah Abo-Elnasr und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Benha University, Benha, Qalubia, Egypt. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of mirabegron in the management of primary nocturnal enuresis.

Methods

This prospective, randomized controlled study included 150 patients randomized into 2 equal groups: desmopressin and mirabegron. All patients underwent evaluation over a 6-month period, with assessments conducted at the end of each month. Evaluations included the frequency of wet nights per month, clinical outcomes, the percentage reduction in wet nights during treatment, and relapse following treatment. The side effects of the drugs in the studied groups were also recorded.

Results

At 2, 3, 4, 5, and 6 months, the mirabegron group showed a significant increase in median percentage reduction in wet nights from baseline compared with the desmopressin group. Furthermore, there was a significant improvement in clinical outcomes for the mirabegron group compared to the desmopressin group (P < .01*). At the 1-month follow-up after treatment, 10.7% of patients in the mirabegron group had a relapse, whereas the relapse rate in the desmopressin group was 22.7%, indicating a statistically significant difference (P = .049*); the relative risk of relapse with mirabegron was 0.47 (95% CI: 0.22-1.02). The mirabegron group exhibited a significant increase in maximum bladder capacity (MBC) (270.8 ± 73.80) compared to the desmopressin group (230.933 ± 67.35; P < .001). Both groups exhibited a statistically significant increase in MBC posttreatment compared with pretreatment (P < .001*). No significant difference was observed between the 2 groups regarding any of the reported side effects.

Conclusion

Mirabegron is an effective treatment for nocturnal enuresis, with better outcomes, fewer relapses, and tolerable side effects. Cite this article as: Abo-Elnasr HA, Alhefnawy MA, Farag M, El Gharably MA. Efficacy and safety of mirabegron 25 mg versus oral desmopressin 120 mcg in treatment of primary nocturnal enuresis. Urol Res Pract. 2026, 52, 0009, doi: 10.5152/ tud.2026.26009.

Autor:innen und Institutionen

  • Department of Urology, Benha University, Benha, Qalubia, Egypt.
  • Department of Urology, Cairo University Kasralainy School of Medicine, Cairo, Egypt ; Department of Urology, Southend University Hospital, Mid and South Essex NHS Foundation Trust, Essex, UK.

Zitieren

APA

Abo-Elnasr, H. A., Alhefnawy, M. A., Farag, M., & El Gharably, M. A. (2026). Efficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis. Urology Research and Practice, 52, 1-9. https://doi.org/10.5152/tud.2026.26009

Vancouver

Abo-Elnasr HA, Alhefnawy MA, Farag M, El Gharably MA. Efficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis. Urology Research and Practice. 2026;52:1-9. doi:10.5152/tud.2026.26009

BibTeX
@article{AboElnasr2026,
  author = {Abo-Elnasr, Hosam Abdel-Fattah and Alhefnawy, Mohamed Abdelrahman and Farag, Mahmoud and El Gharably, Mohamed Aboulfotouh},
  title = {Efficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis},
  journal = {Urology Research and Practice},
  year = {2026},
  volume = {52},
  pages = {1--9},
  doi = {10.5152/tud.2026.26009}
}
Kostenlos starten →